Recurrent VTE · people requiring treatment for acute DVT
1 finding from 1 review
Major bleeding · people requiring treatment for acute DVT
1 finding from 1 review
Pulmonary embolism · people requiring treatment for acute DVT
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for acute DVT
1 finding from 1 review
Post‐thrombotic syndrome · people requiring treatment for acute DVT
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes post‐thrombotic syndrome compared with BMP alone (very low certainty).
1 finding from 1 review
Adverse events · people requiring treatment for acute DVT
It is very uncertain whether acute DVT ‐ antiplatelet agents plus BMP changes adverse events compared with BMP alone (very low certainty).
1 finding from 1 review
Mortality ‐ early and intermediate · people requiring treatment for chronic DVT
1 finding from 1 review
Post‐thrombotic syndrome · people requiring treatment for chronic DVT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people requiring treatment for chronic DVT
1 finding from 1 review
Recurrent VTE · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in pulmonary embolism (fatal/non‐fatal) compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Mortality ‐ intermediate and long term · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in mortality ‐ intermediate and long term compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Post‐thrombotic syndrome · people requiring treatment for chronic DVT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in adverse events compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Recurrent VTE ‐ early and intermediate · people requiring treatment for chronic DVT
It is very uncertain whether chronic DVT ‐ antiplatelet agents plus BMP changes recurrent VTE ‐ early and intermediate compared with BMP alone (very low certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
1 finding from 1 review
Pulmonary embolism · people requiring treatment for chronic DVT
1 finding from 1 review
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent may leads to higher any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review